{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:47:25Z","timestamp":1793731645429,"version":"4.6.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100020230","name":"Health Commission of Jilin Province","doi-asserted-by":"publisher","award":["2020SC2T062"],"award-info":[{"award-number":["2020SC2T062"]}],"id":[{"id":"10.13039\/501100020230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07697-y","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T01:43:24Z","timestamp":1768182204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Triple-remodeling of tumor microenvironment through hyaluronidase-assisted folate-targeted lipid nanoparticle-mediated siVEGF\/siPD-L1 for enhanced tumor immunotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luquan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"7697_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1126\/science.1249481","volume":"342","author":"M McNutt","year":"2013","unstructured":"McNutt M. Cancer immunotherapy. Science. 2013;342:1417\u20131417.","journal-title":"Science"},{"key":"7697_CR2","doi-asserted-by":"publisher","first-page":"106700","DOI":"10.1016\/j.intimp.2020.106700","volume":"86","author":"S Tang","year":"2020","unstructured":"Tang S, Ning Q, Yang L, Mo ZC, Tang SS. Mechanisms of immune escape in the cancer immune cycle. Int Immunopharmacol. 2020;86:106700.","journal-title":"Int Immunopharmacol"},{"key":"7697_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12967-024-05134-6","volume":"22","author":"YX Chen","year":"2024","unstructured":"Chen YX, Yu DN, Qian H, Shi YH, Tao ZM. CD8+ T cell-based cancer immunotherapy. J Translational Med. 2024;22:394.","journal-title":"J Translational Med"},{"key":"7697_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","volume":"17","author":"JD Martin","year":"2020","unstructured":"Martin JD, Cabral H, Stylianopoulos T, Jain RK. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Reviews Clin Oncol. 2020;17:251\u201366.","journal-title":"Nat Reviews Clin Oncol"},{"key":"7697_CR5","doi-asserted-by":"publisher","first-page":"e009063","DOI":"10.1136\/jitc-2024-009063","volume":"12","author":"LA Emens","year":"2024","unstructured":"Emens LA, Romero PJ, Anderson AC, Bruno TC, Capitini CM, Collyar D, Gulley JL, Hwu P, Posey AJr, Silk AW, Wargo JA. Challenges and opportunities in cancer immunotherapy: a society for immunotherapy of cancer (SITC) strategic vision. J Immunother Cancer. 2024;12:e009063.","journal-title":"J Immunother Cancer"},{"key":"7697_CR6","doi-asserted-by":"publisher","first-page":"1902440","DOI":"10.1002\/adfm.201902440","volume":"29","author":"HR Wang","year":"2019","unstructured":"Wang HR, Han X, Dong ZL, Xu J, Wang J, Liu Z. Hyaluronidase with pH-responsive dextran modification as an adjuvant nanomedicine for enhanced Photodynamic-Immunotherapy of cancer. Adv Funct Mater. 2019;29:1902440.","journal-title":"Adv Funct Mater"},{"key":"7697_CR7","doi-asserted-by":"publisher","first-page":"120114","DOI":"10.1016\/j.biomaterials.2020.120114","volume":"252","author":"YY Hu","year":"2020","unstructured":"Hu YY, Lin L, Chen J, Maruyama A, Tian HY, Chen XS. Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger. Biomaterials. 2020;252:120114.","journal-title":"Biomaterials"},{"key":"7697_CR8","doi-asserted-by":"publisher","first-page":"eabc7828","DOI":"10.1126\/sciadv.abc7828","volume":"6","author":"JY Wu","year":"2020","unstructured":"Wu JY, Chen J, Feng YJ, Zhang SJ, Lin L, Guo ZP, Sun PJ, Xu CN, Tian HY, Chen XS. An immune cocktail therapy to realize multiple boosting of the cancer-immunity cycle by combination of drug\/gene delivery nanoparticles. Sci Adv. 2020;6:eabc7828.","journal-title":"Sci Adv"},{"key":"7697_CR9","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1158\/1078-0432.CCR-15-2010","volume":"22","author":"SR Hingorani","year":"2016","unstructured":"Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R, et al. Phase Ib study of pegylated Recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Cancer Res. 2016;22:2848\u201354.","journal-title":"Clin Cancer Res"},{"key":"7697_CR10","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1158\/1538-7445.AM2016-4886","volume":"76","author":"S Rosengren","year":"2016","unstructured":"Rosengren S, Clift R, Zimmerman SJ, Souratha J, Thompson BJ, Blouw B, Li X, Zhao Q, Shepard M, Maneval DC, et al. PEGylated Recombinant hyaluronidase PH20 (PEGPH20) enhances checkpoint inhibitor efficacy in syngeneic mouse models of cancer. Cancer Res. 2016;76:4886.","journal-title":"Cancer Res"},{"key":"7697_CR11","doi-asserted-by":"publisher","first-page":"101915","DOI":"10.1016\/j.nantod.2023.101915","volume":"51","author":"XY Guo","year":"2023","unstructured":"Guo XY, Wu JY, Feng YJ, Yang ZY, Fang HP, Chen J, Guo ZP, Lin L, Pang X, Tian HY. Gemini nanoparticles-based quadruple therapy (GNQT) achieved effective tumor immunotherapy by comprehensive regulation of tumor microenvironment. Nano Today. 2023;51:101915.","journal-title":"Nano Today"},{"key":"7697_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Therapy. 2023;8:198.","journal-title":"Signal Transduct Target Therapy"},{"key":"7697_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00210-019-01629-y","volume":"392","author":"AWK Yeung","year":"2019","unstructured":"Yeung AWK, Abdel-Daim MM, Abushouk AI, Kadonosono K. A literature analysis on anti-vascular endothelial growth factor therapy (anti-VEGF) using a bibliometric approach. Naunyn-Schmiedebergs Archives Pharmacol. 2019;392:393\u2013403.","journal-title":"Naunyn-Schmiedebergs Archives Pharmacol"},{"key":"7697_CR14","doi-asserted-by":"publisher","first-page":"101194","DOI":"10.1016\/j.nantod.2021.101194","volume":"38","author":"YJ Feng","year":"2021","unstructured":"Feng YJ, Wu JY, Chen J, Lin L, Zhang SJ, Yang ZY, Sun PJ, Li YH, Tian HY, Chen XS. Targeting dual gene delivery nanoparticles overcomes immune checkpoint Blockade induced adaptive resistance and regulates tumor microenvironment for improved tumor immunotherapy. Nano Today. 2021;38:101194.","journal-title":"Nano Today"},{"key":"7697_CR15","doi-asserted-by":"publisher","first-page":"47785","DOI":"10.1021\/acsami.9b18144","volume":"11","author":"HP Fang","year":"2019","unstructured":"Fang HP, Chen J, Lin L, Liu F, Tian HY, Chen XS. A strategy of killing three birds with one stone for cancer therapy through regulating the tumor microenvironment by H2O2-Responsive gene delivery system. ACS Appl Mater Interfaces. 2019;11:47785\u201397.","journal-title":"ACS Appl Mater Interfaces"},{"key":"7697_CR16","doi-asserted-by":"publisher","first-page":"116659","DOI":"10.1016\/j.biopha.2024.116659","volume":"175","author":"F Chen","year":"2024","unstructured":"Chen F, Sheng J, Li XP, Gao ZF, Zhao SQ, Hu LY, Chen MJ, Fei JG, Song ZW. Unveiling the promise of PD1\/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma. Biomed Pharmacother. 2024;175:116659.","journal-title":"Biomed Pharmacother"},{"key":"7697_CR17","doi-asserted-by":"publisher","first-page":"101603","DOI":"10.1016\/j.mtbio.2025.101603","volume":"31","author":"JS Zhou","year":"2025","unstructured":"Zhou JS, Li YY, Jiang XH, Xin ZY, Liu WS, Zhang XY, Zhai YH, Zhang ZZ, Shi T, Xue MH, et al. PD-L1 SiRNA incorporation into a cationic liposomal tumor mRNA vaccine enhances cytotoxic T cell activation and prevents immune evasion. Mater Today Bio. 2025;31:101603.","journal-title":"Mater Today Bio"},{"key":"7697_CR18","doi-asserted-by":"publisher","first-page":"116203","DOI":"10.1016\/j.biopha.2024.116203","volume":"171","author":"JW Cui","year":"2024","unstructured":"Cui JW, Li Y, Yang Y, Yang HK, Dong JM, Xiao ZH, He X, Guo JH, Wang RQ, Dai B, Zhou ZL. Tumor immunotherapy resistance: revealing the mechanism of PD-1 \/ PD-L1-mediated tumor immune escape. Biomed Pharmacother. 2024;171:116203.","journal-title":"Biomed Pharmacother"},{"key":"7697_CR19","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 Blockade. Proc Natl Acad Sci USA. 2002;99:12293\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7697_CR20","doi-asserted-by":"publisher","first-page":"731798","DOI":"10.3389\/fphar.2021.731798","volume":"12","author":"JH Liu","year":"2021","unstructured":"Liu JH, Chen ZC, Li YQ, Zhao WJ, Wu JB, Zhang Z. PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol. 2021;12:731798.","journal-title":"Front Pharmacol"},{"key":"7697_CR21","doi-asserted-by":"publisher","first-page":"102179","DOI":"10.1016\/j.eclinm.2023.102179","volume":"63","author":"AV Kulkarni","year":"2023","unstructured":"Kulkarni AV, Tevethia H, Kumar K, Premkumar M, Muttaiah MD, Hiraoka A, Hatanaka T, Tada T, Kumada T, Kakizaki S, et al. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Eclinicalmedicine. 2023;63:102179.","journal-title":"Eclinicalmedicine"},{"key":"7697_CR22","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu AX, Abbas AR, de Galarreta MR, Guan YH, Lu S, Koeppen H, Zhang WJ, Hsu CH, He AR, Ryoo BY, et al. Molecular correlates of clinical response and resistance to Atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28:1599\u2013611.","journal-title":"Nat Med"},{"key":"7697_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12967-024-05104-y","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Zhang CG, Jiang AM, Lin AQ, Liu ZQ, Cheng XS, Wang WT, Cheng Q, Zhang J, Wei T, Luo P. Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. J Translational Med. 2024;22:293.","journal-title":"J Translational Med"},{"key":"7697_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi M, Jiao DC, Qin S, Chu Q, Wu KM, Li AP. Synergistic effect of immune checkpoint Blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18:60.","journal-title":"Mol Cancer"},{"key":"7697_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","volume":"6","author":"AI Minchinton","year":"2006","unstructured":"Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583\u201392.","journal-title":"Nat Rev Cancer"},{"key":"7697_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10695-018-0556-3","volume":"45","author":"MAO Dawood","year":"2019","unstructured":"Dawood MAO, Koshio S, Zaineldin AI, Van Doan H, Moustafa EM, Abdel-Daim MM, Esteban MA, Hassaan MS. Dietary supplementation of selenium nanoparticles modulated systemic and mucosal immune status and stress resistance of red sea Bream. Fish Physiol Biochem. 2019;45:219\u201330.","journal-title":"Fish Physiol Biochem"},{"key":"7697_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.etap.2019.03.016","volume":"69","author":"MM Abdel-Daim","year":"2019","unstructured":"Abdel-Daim MM, Eissa IAM, Abdeen A, Abdel-Latif HMR, Ismail M, Dawood MAO, Hassan AM. Lycopene and Resveratrol ameliorate zinc oxide nanoparticles-induced oxidative stress in nile tilapia. Environ Toxicol Pharmacol. 2019;69:44\u201350.","journal-title":"Environ Toxicol Pharmacol"},{"key":"7697_CR28","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.2147\/IJN.S513688","volume":"20","author":"G Lee","year":"2025","unstructured":"Lee G, Kim J, Yang J, Jang Y, Jang J, Tanaka M, Niepa THR, Lee H, Choi J. FOLR1-Targeted Oxygen-Delivering nanosomes enhance Chemo-Induced apoptosis in hypoxic cancer. Int J Nanomed. 2025;20:6875\u201389.","journal-title":"Int J Nanomed"},{"key":"7697_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2022.02.017","volume":"344","author":"M Maeki","year":"2022","unstructured":"Maeki M, Uno S, Niwa A, Okada Y, Tokeshi M. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. J Controlled Release. 2022;344:80\u201396.","journal-title":"J Controlled Release"},{"key":"7697_CR30","doi-asserted-by":"publisher","first-page":"2106580","DOI":"10.1002\/smll.202106580","volume":"18","author":"Y Liu","year":"2022","unstructured":"Liu Y, Yang GZ, Hui Y, Ranaweera S, Zhao CX. Microfluidic nanoparticles for drug delivery. Small. 2022;18:2106580.","journal-title":"Small"},{"key":"7697_CR31","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","volume":"52","author":"JA Kulkarni","year":"2019","unstructured":"Kulkarni JA, Witzigmann D, Chen S, Cullis PR, van der Meel R. Lipid nanoparticle technology for clinical translation of SiRNA therapeutics. Acc Chem Res. 2019;52:2435\u201344.","journal-title":"Acc Chem Res"},{"key":"7697_CR32","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3390\/biom11030392","volume":"11","author":"MT Kabir","year":"2021","unstructured":"Kabir MT, Rahman MH, Akter R, Behl T, Kaushik D, Mittal V, Pandey P, Akhtar MF, Saleem A, Albadrani GM, et al. Potential role of Curcumin and its nanoformulations to treat various types of cancers. Biomolecules. 2021;11:392.","journal-title":"Biomolecules"},{"key":"7697_CR33","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3390\/cells9092061","volume":"9","author":"S Hager","year":"2020","unstructured":"Hager S, Fittler FJ, Wagner E, Bros M. Nucleic Acid-Based approaches for tumor therapy. Cells. 2020;9:2061.","journal-title":"Cells"},{"key":"7697_CR34","doi-asserted-by":"publisher","first-page":"114113","DOI":"10.1016\/j.addr.2022.114113","volume":"182","author":"G Kara","year":"2022","unstructured":"Kara G, Calin GA, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022;182:114113.","journal-title":"Adv Drug Deliv Rev"},{"key":"7697_CR35","first-page":"S77","volume":"12","author":"E Wagner","year":"2007","unstructured":"Wagner E. Advances in cancer gene therapy: tumor-targeted delivery of therapeutic pDNA, siRNA, and DsRNA nucleic acids. J Buon. 2007;12:S77\u201382.","journal-title":"J Buon"},{"key":"7697_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0169-409X(99)00062-9","volume":"41","author":"J Sudimack","year":"2000","unstructured":"Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41:147\u201362.","journal-title":"Adv Drug Deliv Rev"},{"key":"7697_CR37","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1039\/D0NR07622H","volume":"13","author":"L Duan","year":"2021","unstructured":"Duan L, Xu LM, Xu X, Qin ZA, Zhou XY, Xiao Y, Liang YJ, Xia J. Exosome-mediated delivery of gene vectors for gene therapy. Nanoscale. 2021;13:1387\u201397.","journal-title":"Nanoscale"},{"key":"7697_CR38","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jconrel.2023.09.001","volume":"362","author":"J Casper","year":"2023","unstructured":"Casper J, Schenk SH, Parhizkar E, Detampel P, Dehshahri A, Huwyler J. Polyethylenimine (PEI) in gene therapy: current status and clinical applications. J Controlled Release. 2023;362:667\u201391.","journal-title":"J Controlled Release"},{"key":"7697_CR39","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/cells8091102","volume":"8","author":"J J\u00e1szai","year":"2019","unstructured":"J\u00e1szai J, Schmidt MHH. Trends and challenges in tumor Anti-Angiogenic therapies. Cells. 2019;8:1102.","journal-title":"Cells"},{"key":"7697_CR40","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. 2024;57:206\u201322.","journal-title":"Immunity"},{"key":"7697_CR41","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","volume":"187","author":"LP Andrews","year":"2024","unstructured":"Andrews LP, Butler SC, Cui J, Cillo AR, Cardello C, Liu C, Brunazzi EA, Baessler A, Xie BX, Kunning SR, et al. LAG-3 and PD-1 synergize on CD8\u2009+\u2009T cells to drive T cell exhaustion and hinder autocrine IFN-y-dependent anti-tumor immunity. Cell. 2024;187:4355\u201372.","journal-title":"Cell"},{"key":"7697_CR42","first-page":"219","volume":"15","author":"Z Bakridin","year":"2025","unstructured":"Bakridin Z, Ilnur A, Azamat N, Markhabo R, Gulsara A, Zavqiddin R, Khudoyshukur B, Azamat N, Olimjon J, Sardor Z, et al. Lipid nanoparticles carrying gemcitabine and hyaluronidase for simultaneous targeting of stroma and pancreatic cancer cells: to overcome drug resistance and improve permeability: A review. J Nanostruct. 2025;15:219\u201328.","journal-title":"J Nanostruct"},{"key":"7697_CR43","doi-asserted-by":"publisher","first-page":"e006401","DOI":"10.1136\/jitc-2022-006401","volume":"11","author":"MM Melssen","year":"2023","unstructured":"Melssen MM, Sheybani ND, Leick KM. Slingluff cjr: barriers to immune cell infiltration in tumors. J Immunother Cancer. 2023;11:e006401.","journal-title":"J Immunother Cancer"},{"key":"7697_CR44","doi-asserted-by":"publisher","first-page":"19295","DOI":"10.1021\/acsami.0c02769","volume":"12","author":"J Chen","year":"2020","unstructured":"Chen J, Guo P, Jiao ZX, Lin L, Xu CN, Tian HY, Chen XS. Poly(L-glutamic acid)-Based zwitterionic polymer in a charge conversional shielding system for gene therapy of malignant tumors. ACS Appl Mater Interfaces. 2020;12:19295\u2013306.","journal-title":"ACS Appl Mater Interfaces"},{"key":"7697_CR45","doi-asserted-by":"publisher","first-page":"915094","DOI":"10.3389\/fimmu.2022.915094","volume":"13","author":"XT Zhou","year":"2022","unstructured":"Zhou XT, Ni YH, Liang X, Lin Y, An B, He X, Zhao X. Mechanisms of tumor resistance to immune checkpoint Blockade and combination strategies to overcome resistance. Front Immunol. 2022;13:915094.","journal-title":"Front Immunol"},{"key":"7697_CR46","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng ZY, Li GY, Xiong W, Yi M, Xiang B. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23:108.","journal-title":"Mol Cancer"},{"key":"7697_CR47","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/pharmaceutics13071009","volume":"13","author":"D Hattab","year":"2021","unstructured":"Hattab D, Gazzali AM, Bakhtiar A. Clinical advances of siRNA-Based nanotherapeutics for cancer treatment. Pharmaceutics. 2021;13:1009.","journal-title":"Pharmaceutics"},{"key":"7697_CR48","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","volume":"23","author":"Q Tang","year":"2024","unstructured":"Tang Q, Khvorova A. RNAi-based drug design: considerations and future directions. Nat Rev Drug Discovery. 2024;23:341\u201364.","journal-title":"Nat Rev Drug Discovery"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07697-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07697-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07697-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:13:19Z","timestamp":1768342399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07697-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7697"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07697-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in compliance with the Institutional Animal Care and Use Committee of Jilin University School of Pharmaceutical Science (No. 20250033).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}